Adamas: Forest submits NDA for AD combo pill, PD therapy in the works
By Randy Osborne
Tuesday, March 4, 2014
With a wholly owned drug for Parkinson’s disease (PD) at the phase III stage, Adamas Pharmaceuticals Inc. said Forest Laboratories Inc. – its partner for a combo Alzheimer’s disease (AD) therapy – submitted a new drug application (NDA) to the FDA for the once-daily capsule MDX-8704 to treat AD-related dementia.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.